Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 14/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24770696 | 0.87 | PCSK9 (0.80) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL24769080 | 0.86 | PCSK9 (1.00) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL31575437 | 0.85 | PCSK9 (0.83) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL24770688 | 0.85 | PCSK9 (0.82) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL12604460 | 0.84 | PCSK9 (1.00) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL31575397 | 0.83 | PCSK9 (0.94) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL31575391 | 0.83 | PCSK9 (0.81) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL31575436 | 0.82 | PCSK9 (0.88) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL31575428 | 0.81 | PCSK9 (0.79) | PCSK9LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL13789898 | 0.80 | TP53 (0.73) | PCSK9HTTALDH1A1TP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352022-A1 | GROUP OF IMB-C5 SERIES COMPOUNDS HAVING ANTI-CORONAVIRUS ACTIVITY AND APPLICATION THEREOF | INSTITUTE OF MEDICINAL BIOTECHNOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2024-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352022-A1 | GROUP OF IMB-C5 SERIES COMPOUNDS HAVING ANTI-CORONAVIRUS ACTIVITY AND APPLICATION THEREOF | ACE2, C5, ACE | PCSK9 119/4885LMNA 348/4885SMN1; SMN2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.